Neal Koller

Neal Koller has had extensive work experience in various roles and positions. Neal currently serves as the Chairman of the Board of Directors and CEO at Alphyn Biologics, Inc., a clinical-stage life science company that specializes in developing first-in-class Multi-Target Therapeutics™ for severe and prevalent skin diseases. Neal is responsible for leading the development of the company's lead drug candidate, AB-101a, a topical treatment for atopic dermatitis.

Prior to their current role, Neal was the Chairman of the Board of Directors, President, and CEO at PGT Holdings, Inc. from 2015 to 2022. Neal also served as the President and CEO, as well as a member of the Board of Directors, at Perthera, Inc. from 2017 to 2018. Before that, they held the position of President and CEO, as well as a member of the Board of Directors, at Plurogen Therapeutics, Inc. from 2006 to 2017.

Neal's career began at Sherwood Davis & Geck in 1980, where they served in various roles, including Division President, Corporate Vice President of Business Development, and Vice President of Marketing. Neal held these positions for over 18 years, gaining extensive experience in global corporate positions and leading high-growth business units.

Neal has also been involved in other companies such as Welcare Industries, PDA, Inc., Dovetail Technologies, Inc., and Sound Diagnostics, Inc., where they held executive positions and played crucial roles in their development and success.

Overall, their work experience showcases their expertise and leadership in the biotechnology and healthcare industries, with a focus on developing innovative therapies and leading companies to growth and success.

Neal Koller has a Bachelor of Science degree in Biology from the University of Richmond. Neal also has completed the Advanced Management Series in Strategic Product Planning at the University of Michigan, and the Executive MBA Series in Economics at Washington University in St. Louis.